13F-HR filed by Lynx1 Capital Management LP
Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:13:54 UTC, with 31 holding rows worth $646,092,908.
- Accession
- 0001910456-26-000007
- Filer
- CIK 1910456
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 31 entries on the cover page, a total value of $646,092,908 stated on the cover page (in dollars after the unit check, H1), rows summing to $646,092,908 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerLynx1 Capital Advisors LLC028-22145
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 13,263,288 | $311,422,002 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 8,963,500 | $137,589,725 | dollars as filed | |
| STOKE THERAPEUTICS INC | 86150R107 | COM | 3,896,169 | $101,300,394 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 7,530,915 | $25,077,947 | dollars as filed | |
| PRECISION BIOSCIENCES INC | 74019P207 | COM NEW | 2,758,215 | $17,266,426 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 472,606 | $15,714,150 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 1,544,980 | $15,310,752 | dollars as filed | |
| NEUPHORIA THERAPEUTICS INC | 64136E102 | COM | 875,328 | $3,116,168 | dollars as filed | |
| PASSAGE BIO INC | 702712209 | COM NEW | 673,759 | $3,031,914 | dollars as filed | |
| PROQR THERAPEUTICS NV | N71542109 | SHS EURO | 1,562,093 | $2,593,074 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 8,019,148 | $2,522,022 | dollars as filed | |
| KAZIA THERAPEUTICS LTD | 48669G303 | SPONSORED ADS | 225,800 | $2,166,551 | dollars as filed | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 1,798,070 | $1,941,916 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 278,606 | $1,769,148 | dollars as filed | |
| SURROZEN INC | 86889P208 | COMMON STOCK | 20,000 | $643,600 | dollars as filed | |
| IMMATICS N.V | N44445109 | SHS | 71,263 | $625,689 | dollars as filed | |
| WEREWOLF THERAPEUTICS INC | 95075A107 | CMN | 657,786 | $606,676 | dollars as filed | |
| Yarrow Bioscience, Inc. | 92941V407 | Common Stock, $0.0001 par value | 22,000 | $495,440 | dollars as filed | |
| XENCOR INC | 98401F105 | COMMON STOCK | 18,194 | $453,940 | dollars as filed | |
| IMMUNOCORE HLDGS PLC ADS | 45258D105 | ADR | 14,300 | $433,147 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 25,000 | $402,750 | dollars as filed | |
| TRAWS PHARMA INC | 68232V884 | COM NEW | 559,470 | $332,213 | dollars as filed | |
| DENALI THERAPEUTICS INC COM | 24823R105 | Stock | 11,658 | $240,971 | dollars as filed | |
| ABSCI CORPORATION | 00091E109 | COM | 21,245 | $228,809 | dollars as filed | |
| FOGHORN THERAPEUTICS INC | 344174107 | COMMON STOCK | 61,588 | $219,869 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 10,100 | $154,833 | dollars as filed | |
| PRIME MEDICINE INC | 74168J101 | COM | 45,000 | $137,475 | dollars as filed | |
| BOLT BIOTHERAPEUTICS INC | 097702203 | COM NEW | 30,800 | $113,344 | dollars as filed | |
| EUPRAXIA PHARMACEUTICALS INC | 29842P105 | COM 298736 AL 3 EURONET WORLDWIDE INC NOTE 0.750% 3/1 | 10,000 | $91,000 | dollars as filed | |
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 16,029 | $89,762 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 20,000 | $1,201 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001910456-26-000007 | this filing | 2026-11-16 |